Compare Stocks: BMEA, AGEN, LXEO, and LYEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$8.20 +4.8%	$4.24	$2.71 ▼ $8.70	$349.96M	1.41	10.99 million shs	2.01 million shs
BMEA Biomea Fusion	$1.23 +2.5%	$1.28	$0.87 ▼ $2.99	$86.76M	-0.28	646,890 shs	622,592 shs
LXEO Lexeo Therapeutics	$4.41 +5.0%	$4.66	$3.99 ▼ $10.99	$329.79M	1.46	952,909 shs	916,805 shs
LYEL Lyell Immunopharma	$13.63 +5.9%	$13.61	$9.28 ▼ $45.00	$315.37M	-0.04	152,888 shs	186,639 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+4.80%	+24.17%	+134.81%	+110.67%	+51.76%
BMEA Biomea Fusion	+2.50%	-1.60%	-12.77%	-23.13%	-23.60%
LXEO Lexeo Therapeutics	+5.00%	+0.46%	-5.97%	-29.21%	-7.55%
LYEL Lyell Immunopharma	+5.91%	+4.93%	-2.99%	-34.63%	+19.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$8.20 +4.8%	$4.24	$2.71 ▼ $8.70	$349.96M	1.41	10.99 million shs	2.01 million shs
BMEA Biomea Fusion	$1.23 +2.5%	$1.28	$0.87 ▼ $2.99	$86.76M	-0.28	646,890 shs	622,592 shs
LXEO Lexeo Therapeutics	$4.41 +5.0%	$4.66	$3.99 ▼ $10.99	$329.79M	1.46	952,909 shs	916,805 shs
LYEL Lyell Immunopharma	$13.63 +5.9%	$13.61	$9.28 ▼ $45.00	$315.37M	-0.04	152,888 shs	186,639 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	+4.80%	+24.17%	+134.81%	+110.67%	+51.76%
BMEA Biomea Fusion	+2.50%	-1.60%	-12.77%	-23.13%	-23.60%
LXEO Lexeo Therapeutics	+5.00%	+0.46%	-5.97%	-29.21%	-7.55%
LYEL Lyell Immunopharma	+5.91%	+4.93%	-2.99%	-34.63%	+19.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.25	Hold	$22.00	168.46% Upside
BMEA Biomea Fusion	2.71	Moderate Buy	$8.50	591.06% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	325.17% Upside
LYEL Lyell Immunopharma	2.75	Moderate Buy	$43.20	216.95% Upside

Current Analyst Ratings Breakdown

Latest BMEA, AGEN, LXEO, and LYEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	AGEN Agenus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $14.00
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2026	LYEL Lyell Immunopharma	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
7/17/2026	LYEL Lyell Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $30.00
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $9.00
6/16/2026	AGEN Agenus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$114.20M	3.21	N/A	N/A	($8.17) per share	-1.00
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.42 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
LYEL Lyell Immunopharma	$40K	8,348.38	N/A	N/A	$11.68 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	$120K	$1.59	5.15	N/A	N/A	50.49%	-31.66%	42.71%	8/6/2026 (Estimated)
BMEA Biomea Fusion	-$61.80M	-$0.68	N/A	N/A	N/A	N/A	-265.37%	-103.96%	N/A
LXEO Lexeo Therapeutics	-$99.96M	-$1.45	N/A	N/A	N/A	N/A	-47.48%	-41.72%	8/13/2026 (Estimated)
LYEL Lyell Immunopharma	-$274.45M	-$13.80	N/A	N/A	N/A	-794,858.12%	-85.71%	-66.41%	8/11/2026 (Estimated)

Latest BMEA, AGEN, LXEO, and LYEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.30	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	LYEL Lyell Immunopharma	-$2.0243	N/A	N/A	N/A	$0.01 million	N/A
8/6/2026	Q2 2026	AGEN Agenus	$0.05	N/A	N/A	N/A	$34.00 million	N/A
5/11/2026	Q1 2026	AGEN Agenus	$2.10	$1.02	-$1.08	$1.02	$129.50 million	$33.74 million
5/11/2026	Q1 2026	BMEA Biomea Fusion	-$0.24	-$0.17	+$0.07	-$0.17	N/A	N/A
5/11/2026	Q1 2026	LXEO Lexeo Therapeutics	-$0.29	-$0.25	+$0.04	-$0.25	N/A	N/A
5/6/2026	Q1 2026	LYEL Lyell Immunopharma	-$1.10	-$1.10	N/A	-$1.10	$0.00 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.38	0.38
BMEA Biomea Fusion	N/A	4.98	4.98
LXEO Lexeo Therapeutics	N/A	14.16	14.16
LYEL Lyell Immunopharma	N/A	7.23	7.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
BMEA Biomea Fusion	96.72%
LXEO Lexeo Therapeutics	60.67%
LYEL Lyell Immunopharma	66.05%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	6.50%
BMEA Biomea Fusion	10.60%
LXEO Lexeo Therapeutics	2.00%
LYEL Lyell Immunopharma	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	44.75 million	41.84 million	Optionable
BMEA Biomea Fusion	50	72.30 million	64.64 million	Optionable
LXEO Lexeo Therapeutics	58	78.52 million	76.95 million	Not Optionable
LYEL Lyell Immunopharma	270	24.50 million	22.99 million	Optionable

BMEA, AGEN, LXEO, and LYEL Headlines

Recent News About These Companies

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday

August 4 at 12:25 PM | marketbeat.com

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts

July 22, 2026 | defenseworld.netD

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of "Moderate Buy" by Brokerages

July 19, 2026 | marketbeat.com

Lyell Immunopharma (NASDAQ:LYEL) Shares Up 6.4% - Here's Why

July 16, 2026 | marketbeat.com

Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet

July 2, 2026 | zacks.com

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ...

June 26, 2026 | enidnews.comE

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 25, 2026 | globenewswire.com

Lyell Immunopharma Shareholders Back Governance at 2026 Meeting

June 15, 2026 | tipranks.com

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European ...

June 14, 2026 | finance.yahoo.com

New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma

June 12, 2026 | quiverquant.comQ

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

June 12, 2026 | globenewswire.com

Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells 1,977 Shares of Stock

June 12, 2026 | insidertrades.com

Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?

June 9, 2026 | finance.yahoo.com

Lyell Immunopharma Reports Significant Reduction in Grade ≥ 2 Diarrhea/Colitis in Phase 1 Trial of LYL273 for Metastatic Colorectal Cancer with GI Prophylaxis

June 8, 2026 | quiverquant.comQ

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

June 8, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion.html$

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

June 4, 2026 | markets.businessinsider.com

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

June 4, 2026 | globenewswire.com

Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

June 4, 2026 | zacks.com

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 1, 2026 | globenewswire.com

Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

May 23, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMEA, AGEN, LXEO, and LYEL Company Descriptions

Agenus NASDAQ:AGEN

$8.20 +0.38 (+4.80%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$8.26 +0.07 (+0.82%)

As of 08:40 AM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Biomea Fusion NASDAQ:BMEA

$1.23 +0.03 (+2.50%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.25 +0.02 (+1.22%)

As of 08:42 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Lexeo Therapeutics NASDAQ:LXEO

$4.41 +0.21 (+5.00%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$4.69 +0.28 (+6.35%)

As of 08:24 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Lyell Immunopharma NASDAQ:LYEL

$13.63 +0.76 (+5.91%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$13.61 -0.02 (-0.15%)

As of 08/4/2026 06:53 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, AGEN, LXEO, and LYEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, AGEN, LXEO, and LYEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, AGEN, LXEO, and LYEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMEA, AGEN, LXEO, and LYEL Company Descriptions

Agenus NASDAQ:AGEN

Biomea Fusion NASDAQ:BMEA

Lexeo Therapeutics NASDAQ:LXEO

Lyell Immunopharma NASDAQ:LYEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMEA, AGEN, LXEO, and LYEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMEA, AGEN, LXEO, and LYEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMEA, AGEN, LXEO, and LYEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMEA, AGEN, LXEO, and LYEL Company Descriptions

Agenus NASDAQ:AGEN

Biomea Fusion NASDAQ:BMEA

Lexeo Therapeutics NASDAQ:LXEO

Lyell Immunopharma NASDAQ:LYEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools